Patents by Inventor Andreas Goessl

Andreas Goessl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140161738
    Abstract: The invention discloses a pharmaceutical hemostatic liquid foam base preparation comprising albumin as foaming agent and a fibrinogen precipitating substance and optionally a coagulation inducing agent, wherein albumin as foaming agent is present in native form; a method for the production of a transient hemostatic liquid foam; the transient hemostatic liquid foam; and a kit for making the foam.
    Type: Application
    Filed: December 6, 2013
    Publication date: June 12, 2014
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Andreas Goessl, Katarzyna Gorna
  • Publication number: 20130287818
    Abstract: Bone hemostat compositions, and methods for their use and manufacture are provided. Exemplary hemostatic compositions include polymeric components such as random and non-random copolymers, natural polymers, ceramics, reactive group polymers, and combinations thereof. Bone compositions may be used during surgical procedures, and may be applied to bone to inhibit or prevent bleeding from bone.
    Type: Application
    Filed: October 29, 2012
    Publication date: October 31, 2013
    Inventors: Katarzyna I. Gorna, Andreas Goessl, Heinz Gulle
  • Patent number: 8377420
    Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: February 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
  • Publication number: 20120128653
    Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) mixing said first component and said second component under conditions effective to form a wet paste while essentially preventing degradation of the second component by said first component in a final container or transferring said wet paste into a final container, d) freezing and lyophilizing said paste in said container thereby obtaining a dry and stable hemostatic composition comprising said first and said second component in lyophilized form, and e) finishing said dry and stable hemostatic composition in said final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.
    Type: Application
    Filed: June 1, 2011
    Publication date: May 24, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
  • Publication number: 20120121532
    Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to. a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.
    Type: Application
    Filed: June 1, 2011
    Publication date: May 17, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
  • Publication number: 20120021058
    Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a dry granular preparation of a biocompatible polymer suitable for use in hemostasis, b) coating the granules in said dry granular preparation with a preparation of a coagulation inducing agent, thereby obtaining coagulation inducing agent coated polymer granules, c) filling said coagulation inducing agent coated polymer granules into a final container, d) finishing the final container to a storable pharmaceutical device containing said coagulation inducing agent coated polymer granules as a dry and stable hemostatic composition.
    Type: Application
    Filed: June 1, 2011
    Publication date: January 26, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventor: Andreas Goessl
  • Publication number: 20110117027
    Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.
    Type: Application
    Filed: January 11, 2011
    Publication date: May 19, 2011
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
  • Publication number: 20100233269
    Abstract: A process for mineralizing a particulate organic material includes providing particles of a non-porous, swellable organic material, and contacting the particles with a solution containing at least one cation and a solution containing at least one anion, thereby obtaining the mineralized particulate organic material.
    Type: Application
    Filed: March 12, 2010
    Publication date: September 16, 2010
    Applicants: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Katarzyna Gorna, Andreas Goessl
  • Publication number: 20080260714
    Abstract: A composition for use in bone healing and bone regeneration in the form of a viscoelastic hydrogel gel or liquid formulation comprising fibrinogen, thrombin and an inorganic component comprising a strontium (Sr) containing compound and/or possibly another metal such as a calcium containing compound. The strontium containing compound can be dissolved in the thrombin solutions or added to the clot in crystalline particulate form. Upon mixing the components, gelation takes place to form a matrix. The composition may also comprise an iodine-containing compound which acts as a plasticizer.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 23, 2008
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: John J. Barry, Andreas Goessl, Gerald Zimmer
  • Publication number: 20080241072
    Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.
    Type: Application
    Filed: March 25, 2008
    Publication date: October 2, 2008
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
  • Publication number: 20070276505
    Abstract: The present invention relates to a biodegradable fibrin based composition for injection into osseous defects or voids, which can be the result of osteoporosis, surgery, bone cysts, tumor removal or traumatic bone injury.
    Type: Application
    Filed: April 17, 2007
    Publication date: November 29, 2007
    Applicants: Baxter International Inc., Baxter Healthcare, S.A.
    Inventors: John Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
  • Publication number: 20070275028
    Abstract: The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.
    Type: Application
    Filed: April 17, 2007
    Publication date: November 29, 2007
    Applicants: Baxter International Inc., Baxter Healthcare, S.A.
    Inventors: John Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban